source
- Otsuka and Ionis report ALS drug ulefnersen meets primary endpoint in phase 3 trialOtsuka and Ionis have completed the Fusion phase 3 trial of ulefnersen, an RNA‑targeted therapy for ALS patients with mutations in the FUS gene. The study enrolled 89 participants, with 73 forming…
- Novo aims to increase oral Wegovy manufacturing capacity tenfold by 2030Novo announced at its Capital Markets Day that it plans to expand the manufacturing capacity for its oral GLP-1 drug Wegovy by a factor of ten by the end of the decade. The company said about 1.5…